87 related articles for article (PubMed ID: 11371940)
1. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.
Szostak MJ; Kaur P; Amin P; Jacobs SC; Kyprianou N
J Urol; 2001 Jun; 165(6 Pt 1):2126-30. PubMed ID: 11371940
[TBL] [Abstract][Full Text] [Related]
2. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.
Mackey TJ; Borkowski A; Amin P; Jacobs SC; Kyprianou N
Urology; 1998 Dec; 52(6):1085-90. PubMed ID: 9836559
[TBL] [Abstract][Full Text] [Related]
3. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
5. Prostate brachytherapy: treatment strategies.
Stone NN; Stock RG
J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis in prostate cancer: bax correlation with stage.
Amirghofran Z; Monabati A; Gholijani N
Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
8. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression.
Tu H; Jacobs SC; Borkowski A; Kyprianou N
Int J Cancer; 1996 Oct; 69(5):357-63. PubMed ID: 8900367
[TBL] [Abstract][Full Text] [Related]
9. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
[TBL] [Abstract][Full Text] [Related]
10. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
[TBL] [Abstract][Full Text] [Related]
11. Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy.
Schellhammer PF; el-Mahdi AM; Higgins EM; Schultheiss TE; Ladaga LE; Babb TJ
J Urol; 1987 May; 137(5):897-901. PubMed ID: 3106654
[TBL] [Abstract][Full Text] [Related]
12. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
14. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
15. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E
J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
17. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
[TBL] [Abstract][Full Text] [Related]
18. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy.
Rakozy C; Grignon DJ; Sarkar FH; Sakr WA; Littrup P; Forman J
Mod Pathol; 1998 Sep; 11(9):892-9. PubMed ID: 9758370
[TBL] [Abstract][Full Text] [Related]
19. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients.
Guo Y; Sigman DB; Borkowski A; Kyprianou N
Prostate; 2000 Feb; 42(2):130-6. PubMed ID: 10617870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
